Navigation Links
New Webinar Hosted by Xtalks Prepares Manufacturers for AMNOG Regulations and the Future of Access and Pricing
Date:8/25/2014

Toronto, Canada (PRWEB) August 25, 2014

Introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in 2011 and the resulting requirements for benefit assessment have fundamentally changed the conditions of market access and pharmaceutical pricing in Germany. The aim of this mandatory evaluation of clinical evidence was to limit the cost of pharmaceuticals and tackle the price monopoly of drug manufacturers in Germany.

While this has successfully been achieved, it has also brought with it further implications beyond the immediate German market, particularly for those countries that use Germany as a price reference. The open nature in which the clinical evidence and especially the critical aspects in these assessments is shared publically has potential impact on a product’s value story with payers in many other jurisdictions. For organizations working in this market or utilizing German price points for market access strategy, understanding these interconnections is critical.

Key take aways of this program include:

  •     Understanding of current AMNOG process
  •     Implications of AMNOG evaluation
  •     Impact of publically available assessment on value story
  •     Overview of price discount trends, both average and unique examples
  •     Future growth beyond current AMNOG framework

For more information or to register for this webinar, visit: AMNOG – German Regulation in the Past, Present and Future.

About Xcenda and Herescon
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. In December of 2013, Herescon GmbH, one of the largest research and consulting boutiques in Germany focused on market access and health economics services, joined this experienced team. As part of AmerisourceBergen Corporation, a leading global healthcare solutions company, the combined bench of Xcenda and Herescon consultants supports pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, these collaborative partners help manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders. For more information visit on Xcenda, visit http://www.xcenda.com/. For more information on Herescon, visit http://www.herescon.com/.

About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/sponsorship.ashx.

Contact:
Michelle Tran
Tel: +1 (416) 977-6555 ext 352
Email: mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12116389.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks
2. Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks
3. Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks
4. China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks
5. The Voice of the Patient in Clinical Trials: Hearing It, Understanding It, New Webinar Hosted by Xtalks
6. Protocol Pooling and Point of Distribution (PoD) Clinical Labeling, Live Webinar Hosted by Xtalks
7. Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks
8. The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks
9. Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks
10. Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks
11. Implementing Risk-based Monitoring, Using Oncology Examples, New Webinar July 31st Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Genetics Center (RGC), U.K. Biobank and GSK to generate genetic ... Biobank resource. The initiative will enable researchers to gain valuable ... for a wide range of serious and life threatening diseases. ... Genetic ...
Breaking Biology Technology:
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
(Date:3/9/2017)... , Australia , March 9, 2017 ... data at the prestigious World Lung Imaging Workshop at ... Andreas Fouras , was invited to deliver the latest ... medicine. This globally recognised event brings together leaders at ... the latest developments in lung imaging. ...
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
Breaking Biology News(10 mins):